bevacizumab

Home
Ligands
bevacizumab

GtoPdb Ligand ID: 6771

Synonyms: Avastin® | rhuMAb-VEGF

bevacizumab is an approved drug (FDA (2004), EMA (2005))

Comment: Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars: Amgen's bevacizumab-awwb (Mvasi®) was the first bevacizumab biosimilar to be FDA approved. This and others are listed in the table below.

Name	Trade name	Company	Clinical Phase	Indications
bevacizumab-awwb	Mvasi	Amgen	Approved (FDA 2017)	Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.
bevacizumab-bvzr; PF-06439535	Zirabev	Pfizer	Approved (EMA & FDA 2019)	Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney, cervical and breast cancers, plus recurrent glioblastoma (FDA).
SB8	Aybintio	Samsung Bioepis	Approved (EMA 2020)	Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
FKB238	Equidacent	Centus Biotherapeutics	Approved (EMA 2020)	Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
bevacizumab; MYL-1402O	Abevmy	Mylan	Approved (EMA 2021)	As per originator reference product.
bevacizumab-maly; BEVZ92-MB02	Oyavas; Alymsys	STADA Arzneimittel/Amneal//mAbxience	Approved (EMA 2021; FDA 2022)	As per originator reference product: NOT adjuvant treatment of colon cancer
bevacizumab	Onbevzi	Samsung Bioepis/Biogen	Approved (EMA 2021)	As per originator reference product
bevacizumab-adcd; CT-P16	Vegzelma	Celltrion	Approved (EMA & FDA 2022)	Approved to treat a range of advanced solid tumours in combination with other cancer drugs: Colorectal, breast, ovarian, fallopian tube, peritoneal, and uterine neoplasms, non-small cell lung cancer, and renal cell carcinoma
bevacizumab-tnjn; BAT1706	Avzivi	Bio-Thera Solutions	Approved (FDA 2023)	Approved for use in the treatment of advanced lung and colorectal cancers